Interpace Diagnostics Corp. announced its most recent entrée into expanding its commercial foot print internationally as a result of the adoption of the ThyGenX test by Dr. Richard Payne of Montreal, Quebec. This is the company's initial step in launching its Thyroid products in Canada and, if successful, plans are already in place to expand in to other Provinces and work with the Canadian Health Ministry to secure coverage of both ThyGenX®, the company's oncogene panel assay, and ThyraMir®, the company's micro- RNA based gene expression classifier.  While the present focus is on ThyGenX, interest in expanding testing to ThyraMir has already been expressed, when additional data becomes available.